{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,30]],"date-time":"2026-05-30T10:01:48Z","timestamp":1780135308794,"version":"3.54.0"},"reference-count":12,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,5,30]]},"DOI":"10.7759\/cureus.109914","type":"journal-article","created":{"date-parts":[[2026,5,30]],"date-time":"2026-05-30T09:17:16Z","timestamp":1780132636000},"source":"Crossref","is-referenced-by-count":0,"title":["Rare Leukemic Phase of Follicular Lymphoma With a High-Risk Follicular Lymphoma International Prognostic Index (FLIPI) Score Treated With Bendamustine-Rituximab"],"prefix":"10.7759","author":[{"given":"Niyati","family":"Bansal","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steve","family":"Thomas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sri Gayathri","family":"Shanmugam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.24937","article-title":"Follicular lymphoma: 2018 update on diagnosis and management","volume":"93","author":"Freedman A","year":"2018","unstructured":"Freedman A. Follicular lymphoma: 2018 update on diagnosis and management. Am J Hematol. 2018, 93:296-305. 10.1002\/ajh.24937","journal-title":"Am J Hematol"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2020.11.008","article-title":"Newly diagnosed and relapsed follicular lymphoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up","volume":"32","author":"Dreyling M","year":"2021","unstructured":"Dreyling M, Ghielmini M, Rule S, et al.. Newly diagnosed and relapsed follicular lymphoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2021, 32:298-308. 10.1016\/j.annonc.2020.11.008","journal-title":"Ann Oncol"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2003-12-4434","article-title":"Follicular lymphoma international prognostic index","volume":"104","author":"Solal-C\u00e9ligny P","year":"2004","unstructured":"Solal-C\u00e9ligny P, Roy P, Colombat P, et al.. Follicular lymphoma international prognostic index. Blood. 2004, 104:1258-65. 10.1182\/blood-2003-12-4434","journal-title":"Blood"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2014.59.7534","article-title":"Early relapse of follicular lymphoma after rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone defines patients at high risk for death: an analysis from the National LymphoCare Study","volume":"33","author":"Casulo C","year":"2015","unstructured":"Casulo C, Byrtek M, Dawson KL, et al.. Early relapse of follicular lymphoma after rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone defines patients at high risk for death: an analysis from the National LymphoCare Study. J Clin Oncol. 2015, 33:2516-22. 10.1200\/JCO.2014.59.7534","journal-title":"J Clin Oncol"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2013-11-531327","article-title":"Randomized trial of bendamustine-rituximab or R-CHOP\/R-CVP in first-line treatment of indolent NHL or MCL: the BRIGHT study","volume":"123","author":"Flinn IW","year":"2014","unstructured":"Flinn IW, Van Der Jagt R, Kahl BS, et al.. Randomized trial of bendamustine-rituximab or R-CHOP\/R-CVP in first-line treatment of indolent NHL or MCL: the BRIGHT study. Blood. 2014, 123:2944-52. 10.1182\/blood-2013-11-531327","journal-title":"Blood"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(12)61763-2","article-title":"Bendamustine plus rituximab versus CHOP plus rituximab as first-line treatment for patients with indolent and mantle-cell lymphomas: an open-label, multicentre, randomised, phase 3 non-inferiority trial","volume":"14","author":"Rummel MJ","year":"2013","unstructured":"Rummel MJ, Niederle N, Maschmeyer G, et al.. Bendamustine plus rituximab versus CHOP plus rituximab as first-line treatment for patients with indolent and mantle-cell lymphomas: an open-label, multicentre, randomised, phase 3 non-inferiority trial. Lancet Oncol. 2013, 14:865-73. 10.1016\/S0140-6736(12)61763-2","journal-title":"Lancet Oncol"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.75169","article-title":"Deauville score-based evaluation of interim PET\/CT in follicular lymphoma: a prognostic factor systematic review and meta-analysis","volume":"16","author":"Fonseca JM","year":"2024","unstructured":"Fonseca JM, Zloic SK, Ayogu CI, Marole KK, Ingold GC, Moreira SV, Soato Ratti MA. Deauville score-based evaluation of interim PET\/CT in follicular lymphoma: a prognostic factor systematic review and meta-analysis. Cureus. 2024, 16:e75169. 10.7759\/cureus.75169","journal-title":"Cureus"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2009-01-198580","article-title":"Follicular lymphomas with and without translocation t(14;18) differ in gene expression profiles and genetic alterations","volume":"114","author":"Leich E","year":"2009","unstructured":"Leich E, Salaverria I, Bea S, et al.. Follicular lymphomas with and without translocation t(14;18) differ in gene expression profiles and genetic alterations. Blood. 2009, 114:826-34. 10.1182\/blood-2009-01-198580","journal-title":"Blood"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2020002944","article-title":"Follicular lymphoma t(14;18)-negative is genetically a heterogeneous disease","volume":"4","author":"Nann D","year":"2020","unstructured":"Nann D, Ramis-Zaldivar JE, M\u00fcller I, et al.. Follicular lymphoma t(14;18)-negative is genetically a heterogeneous disease. Blood Adv. 2020, 4:5652-65. 10.1182\/bloodadvances.2020002944","journal-title":"Blood Adv"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2012.48.3990","article-title":"Rates and outcomes of follicular lymphoma transformation in the immunochemotherapy era: a report from the University of Iowa\/MayoClinic Specialized Program of Research Excellence Molecular Epidemiology Resource","volume":"31","author":"Link BK","year":"2013","unstructured":"Link BK, Maurer MJ, Nowakowski GS, et al.. Rates and outcomes of follicular lymphoma transformation in the immunochemotherapy era: a report from the University of Iowa\/MayoClinic Specialized Program of Research Excellence Molecular Epidemiology Resource. J Clin Oncol. 2013, 31:3272-8. 10.1200\/JCO.2012.48.3990","journal-title":"J Clin Oncol"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(10)62175-7","article-title":"Rituximab maintenance for 2 years in patients with high tumour burden follicular lymphoma responding to rituximab plus chemotherapy (PRIMA): a phase 3, randomised controlled trial","volume":"377","author":"Salles G","year":"2011","unstructured":"Salles G, Seymour JF, Offner F, et al.. Rituximab maintenance for 2 years in patients with high tumour burden follicular lymphoma responding to rituximab plus chemotherapy (PRIMA): a phase 3, randomised controlled trial. Lancet. 2011, 377:42-51. 10.1016\/S0140-6736(10)62175-7","journal-title":"Lancet"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1007\/s00277-021-04452-9","article-title":"Primary prophylaxis of bacterial infections and Pneumocystis jirovecii pneumonia in patients with hematologic malignancies and solid tumors: 2020 updated guidelines of the Infectious Diseases Working Party of the German Society of Hematology and Medical Oncology (AGIHO\/DGHO)","volume":"100","author":"Classen AY","year":"2021","unstructured":"Classen AY, Henze L, von Lilienfeld-Toal M, et al.. Primary prophylaxis of bacterial infections and Pneumocystis jirovecii pneumonia in patients with hematologic malignancies and solid tumors: 2020 updated guidelines of the Infectious Diseases Working Party of the German Society of Hematology and Medical Oncology (AGIHO\/DGHO). Ann Hematol. 2021, 100:1603-20. 10.1007\/s00277-021-04452-9","journal-title":"Ann Hematol"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/499393-rare-leukemic-phase-of-follicular-lymphoma-with-a-high-risk-follicular-lymphoma-international-prognostic-index-flipi-score-treated-with-bendamustine-rituximab","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,30]],"date-time":"2026-05-30T09:17:17Z","timestamp":1780132637000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/499393-rare-leukemic-phase-of-follicular-lymphoma-with-a-high-risk-follicular-lymphoma-international-prognostic-index-flipi-score-treated-with-bendamustine-rituximab"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,30]]},"references-count":12,"URL":"https:\/\/doi.org\/10.7759\/cureus.109914","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2026,5,30]]}}}